Allakos Balance Sheet Health
Financial Health criteria checks 6/6
Allakos has a total shareholder equity of $168.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $243.6M and $74.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$170.79m |
| Equity | US$168.82m |
| Total liabilities | US$74.79m |
| Total assets | US$243.61m |
Recent financial health updates
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01
Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01Recent updates
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 04Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Oct 18Allakos prices ~$150M underwritten offering
Sep 19Allakos falls as lead asset offers mixed results in late-stage trial
Sep 09Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22Allakos: Sad End To A Promising Asset
Dec 23We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth
Aug 16Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
Aug 06Allakos provides lirentelimab clinical trial enrollment updates, names new CMO
Jun 07We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
May 02Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?
Mar 10Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling
Jan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow
Dec 07Allakos EPS misses by $0.02
Nov 09Financial Position Analysis
Short Term Liabilities: ALLK's short term assets ($179.9M) exceed its short term liabilities ($36.6M).
Long Term Liabilities: ALLK's short term assets ($179.9M) exceed its long term liabilities ($38.2M).
Debt to Equity History and Analysis
Debt Level: ALLK is debt free.
Reducing Debt: ALLK had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALLK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALLK has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 29.4% each year.